2017 - IXA
This page contains exclusive content for the member of the following sections: TTS, IXA. Log in to view.
FDA-IXA Workshop - The Challenge of Infection and Risk-Benefit in Xenotransplantation
2.5 - Calibrating the Risk:Benefit Ratio for Clinical Xeno Trial Design
Presenter: David , Sachs, Boston, United States
Authors:
Calibrating the Risk:Benefit Ratio for Clinical Xeno Trial Design
David Sachs, Director, TBRC Laboratories, CTS, Massachusetts General Hospital, Boston, MA, United States
Important Disclaimer
By viewing the material on this site you understand and accept that:
- The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
- The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
- The material is solely for educational purposes for qualified health care professionals.
- The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
- The information cannot be used as a substitute for professional care.
- The information does not represent a standard of care.
- No physician-patient relationship is being established.
Social
Address
International Xenotransplantation Association
C/O The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada